Company Overview

PharmaCielo Ltd. (OTC: PCLOF; formerly listed on the TSX Venture Exchange) is a Canadian-based company focused on the cultivation, extraction, processing, and commercialization of medicinal cannabis-derived products, with core operating assets in Colombia. The company operates within the pharmaceutical cannabis, wellness, and cannabinoid ingredients industries, with an emphasis on low-cost cultivation and large-scale extraction capabilities for international medical cannabis markets. Its primary revenue drivers have included the sale of cannabis extracts, dried flower, and cannabinoid-derived ingredients for pharmaceutical, nutraceutical, and wellness applications.

The company’s operations have historically centered around its Colombian subsidiary PharmaCielo Colombia Holdings S.A.S., which developed cultivation and extraction infrastructure designed to leverage Colombia’s climate, lower labor costs, and agricultural conditions. PharmaCielo was founded during the expansion of the regulated global cannabis industry and evolved from a cultivation-focused enterprise into a company emphasizing medicinal cannabinoid derivatives and international export opportunities. Public disclosures and filings indicate that the company has pursued a vertically integrated operating model combining genetics, cultivation, extraction, processing, and international distribution relationships.

Business Operations

PharmaCielo’s business operations have primarily consisted of cannabis cultivation, extraction, manufacturing, and export activities conducted through its Colombian platform. The company has operated large-scale outdoor cultivation assets and extraction facilities intended to produce cannabinoid oils, isolates, and related derivatives for medical and industrial applications. Revenue generation has historically depended on commercial supply agreements, export authorizations, and downstream product development opportunities in regulated cannabis markets.

The company’s operational footprint has included both Canadian corporate functions and Colombian production assets. PharmaCielo has maintained licenses associated with cultivation, extraction, and cannabis derivative production under Colombia’s regulated medical cannabis framework. Public filings have also referenced relationships with international distributors and strategic commercial partners intended to support access to European and Latin American markets. Data regarding current joint ventures and active commercial partnerships is inconclusive based on available public sources.

Strategic Position & Investments

PharmaCielo’s strategic direction has focused on establishing itself as a low-cost producer of pharmaceutical-grade cannabinoid ingredients for international medical markets. The company has emphasized scalable cultivation capacity, extraction infrastructure, and export-oriented operations as differentiators within the global cannabis supply chain. Management communications and corporate filings have also highlighted efforts to expand value-added cannabinoid products rather than relying solely on bulk cannabis sales.

The company has made significant investments in Colombian cultivation infrastructure, processing facilities, and international regulatory compliance systems. Public disclosures have referenced investments in extraction technologies and pharmaceutical-standard production capabilities designed to support exports into regulated jurisdictions. PharmaCielo has also pursued restructuring and operational optimization initiatives following broader volatility in global cannabis capital markets. Information regarding recent acquisition activity or material portfolio-company investments remains limited in publicly available disclosures.

Geographic Footprint

PharmaCielo is headquartered in Canada, while its principal operational assets have historically been concentrated in Colombia. The company’s cultivation and processing infrastructure has been located primarily in Colombia, where it sought to capitalize on favorable agricultural conditions and lower production costs relative to certain North American cannabis producers.

The company has pursued commercial opportunities across Latin America, Europe, and other international medical cannabis markets through export-oriented operations and distribution relationships. Public filings and corporate materials have referenced regulatory engagement and market development initiatives in multiple jurisdictions, although the scale of active commercial operations outside Colombia has varied over time based on market conditions and regulatory developments.

Leadership & Governance

PharmaCielo was co-founded by a group of entrepreneurs and investors seeking to build a large-scale medicinal cannabis platform centered on Colombian production assets. The company has experienced multiple leadership and governance changes since its early expansion phase, reflecting broader restructuring trends within the cannabis industry. Corporate strategy has generally emphasized operational discipline, international market access, and long-term positioning within regulated medical cannabinoid markets.

Key executives and directors publicly associated with PharmaCielo in recent company disclosures include:

• David Attard – Chief Executive Officer
• Marc Lustig – Chairman
• Bill Petron – Former Chief Financial Officer
• Rene Serafino – Former Chief Executive Officer
• Harpreet S. Sandhu – Director

Public records indicate that leadership has focused on streamlining operations, preserving capital, and pursuing sustainable international cannabis commercialization opportunities. Some executive and board positions have changed over time, and certain current leadership details are inconclusive based on available public sources.